Lexicon Pharmaceuticals, Inc./DE – ‘8-K’ for 9/26/00

On:  Tuesday, 10/10/00, at 9:34am ET   ·   For:  9/26/00   ·   Accession #:  950129-0-4915   ·   File #:  0-30111

in

this entire Filing. an “Entity” Search.

Show

Documents searched

and

each “hit”. the 1st “hit”.

↓↑Hints

Current Report   —   Form 8-K
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 8-K         Lexicon Genetics Incorporated - September 26, 2000     4     11K 
 2: EX-10.1     Lexvision Database & Collaboration Agreement          73    223K 

8-K   —   Lexicon Genetics Incorporated – September 26, 2000
Document Table of Contents

8-K
1st Page of 4
TOC
↑Top
Previous
Next
↓Bottom
Just 1st
 

================================================================================

 UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): SEPTEMBER 26, 2000

 LEXICON GENETICS INCORPORATED
(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)

                                                                [Download Table]
                                                                                 
            DELAWARE                    000-30111                76-0474169      
(STATE OR OTHER JURISDICTION OF  (COMMISSION FILE NUMBER)     (I.R.S. EMPLOYER   
 INCORPORATION OR ORGANIZATION)                            IDENTIFICATION NUMBER)

4000 RESEARCH FOREST DRIVE
THE WOODLANDS, TEXAS 77381
 (ADDRESS OF PRINCIPAL eXECUTIVE
 OFFICES AND ZIP CODE)

(281) 364-0100
 (REGISTRANT'S TELEPHONE NUMBER,
INCLUDING AREA CODE)

================================================================================

8-K
2nd Page of 4
TOC
1st
Previous
Next
↓Bottom
Just 2nd

ITEM 5.           OTHER EVENTS                                                  

    We entered into a database access and license agreement with Bristol-Myers
Squibb Company on September 26, 2000. Bristol-Myers Squibb will have access     
under the agreement to our LexVision(TM) database, which contains phenotypic    
information derived from our gene knockout platform. Scientists use mouse       
knockouts - in which genes are deleted, or "knocked out," of the mouse genome - 
to determine which human gene products are valid targets for the discovery and  
development of new medicines. Bristol-Myers Squibb will also have access to our 
OmniBank library of more than 90,000 mouse embryonic stem cell clones derived   
from our gene-trap technology.                                                  

    The term of the agreement is five years, although either party may
terminate after three years. Under the agreement, we could receive between $15  
million and $25 million in access and delivery fees, in addition to milestones  
and royalties on products Bristol-Myers Squibb develops using our technology.   

ITEM 7.           FINANCIAL STATEMENTS AND EXHIBITS                             

(c)      Exhibits                                             

                                                                [Download Table]

EXHIBIT NO.                           DESCRIPTION                       
-----------                           -----------                       
                                                                        
  +10.1           -- LexVision(TM) Database and Collaboration Agreement,
                     dated September 26, 2000, between Lexicon Genetics 
                     Incorporated and Bristol-Myers Squibb Company.     

---------------------                                                           

+        Confidential treatment has been requested for a portion of this        
      exhibit. The confidential portions of this exhibit have been omitted
   and filed separately with the Securities and Exchange Commission.

2 

8-K
3rd Page of 4
TOC
1st
Previous
Next
↓Bottom
Just 3rd

SIGNATURES

 Pursuant to the requirements of the Securities Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the        
undersigned thereunto duly authorized.                                          

                                           LEXICON GENETICS INCORPORATED

Date:   October 10, 2000                       By: /s/ JEFFREY L. WADE          
                                                  ------------------------------
                                     Jeffrey L. Wade
                                                  Executive Vice President and
                                     General Counsel

3 

8-K
Last Page of 4
TOC
1st
Previous
Next
↓Bottom
Just 4th

 INDEX TO EXHIBITS

                                                                [Download Table]

EXHIBIT NO.                            DESCRIPTION                       
-----------                            -----------                       
                                                                         
  +10.1            -- LexVision(TM) Database and Collaboration Agreement,
                      dated September 26, 2000, between Lexicon Genetics 
                      Incorporated and Bristol-Myers Squibb Company.     

---------------------                                                           

+        Confidential treatment has been requested for a portion of this        
      exhibit. The confidential portions of this exhibit have been omitted
   and filed separately with the Securities and Exchange Commission.

Dates Referenced Herein

				Referenced-On Page
This ‘8-K’ Filing		Date		First		Last			Other Filings
Filed on:		10/10/00		3					None on these Dates
For Period End:		9/26/00		1		4
									List all Filings